Department of Health and Human Services Awarded a Contract to QOOLABS INC for $1,500,000.00

Summary of Award

The contract awarded under the identifier "75N93025C00012" by the US federal government represents a significant partnership between the Department of Health and Human Services (HHS), specifically the National Institutes of Health (NIH), and QOOLABS INC. This contract, amounting to $1,500,000, focuses on the development of affinity reagents for the immune system of guinea pigs, targeting various interleukins such as IL1B, IL2, IL4, IL6, IL8, IL10, IL12, and IL13. These reagents play a critical role in biomedical research and therapeutic developments, targeting immune response modulation which is essential for treating various diseases.

**Award Specifics and Objectives:**

The awarded contract is categorized under a "Definitive Contract" (Type D), implying that it lays out specific requirements and conditions directly without reliance on prior broad-based agreements. The main purpose of this contract is detailed as involving research and development (R&D) services in the sector of health care and applied research, categorized by the product or service code (PSC) "AN12". R&D services like these are fundamental for advancing scientific knowledge and technological capabilities within the biotechnology sector. The North American Industry Classification System (NAICS) code "541714" identifies the contract's niche as biotechnology R&D, excluding nanobiotechnology, emphasizing a focus on practical health and therapeutic applications. This research endeavor is vital for understanding and manipulating the immune system responses in translational research and could have broad implications for developing vaccines or treatments for various ailments. **Contracting Process and Competition:** The contracting process was notably competitive, as evidenced by the details provided: a total of 12 offers were received, and the contract was obtained through full and open competition. The solicitation procedures employed negotiated proposal or quote methods, ensuring a comprehensive evaluation of each bid based on quality, price, and other factors. No particular set-asides or evaluated preferences were applied, indicating an open playing field devoid of specific biases toward smaller or special category businesses. **Recipient and Business Profile:** QOOLABS INC, the recipient of the contract, operates from Carlsbad, California, within San Diego County. The business is characterized by several noteworthy classifications: a U.S.-owned business, a woman-owned small business, self-certified as a small disadvantaged business, and operating under the structure of a corporate entity not exempt from taxes. Such designations often empower small businesses and disadvantaged groups by enabling them to compete for significant governmental contracts, fostering diversity and innovation in federal procurements. The location and concentration of QOOLABS' operations in California, a state known for its technological and scientific advancements, positions them strategically within a community of innovators and potential collaborators. This geographic advantage further supports their capacities to engage in high-level biotech R&D. **Period of Performance and Further Details:** The timeframe outlined for this contract spans from February 1, 2025, to January 31, 2028. This three-year period aligns with typical R&D cycles, allowing ample time for experimentation, product development, and preliminary testing phases before a potential extension or commercialization of the developed reagents. Given the firm-fixed pricing arrangements, detailed as "J" with firm fixed price specifications, QOOLABS INC is assured of consistent funding without fluctuations due to market changes or unexpected costs—facilitating focus entirely on the project’s goals rather than financial stability concerns. **Transactions Overview:** There are two main transactions recorded under this contract. The initial transaction, dated January 14, 2025, included a considerable obligation of $1,500,000, solidifying the agreement financially. This was the foundational financial commitment necessary to initiate the project's activities. The subsequent transaction, executed on April 10, 2025, marked a modification tagged as "P00001." Although it had no additional financial expenditure, it signifies administrative or logistical adjustments to the existing contract, which are common in complex, long-term research deployments to account for evolving research needs or objectives. **Conclusion:** In summary, this contract highlights a strategic alignment of federal resources and private sector innovation through QOOLABS INC. With full competition and robust research objectives, the initiative stands to contribute significantly to the scientific community's understanding of immune system responses in guinea pigs, offering potential translational applications for human health advancements. As such, it emphasizes the government's role in spearheading and financing groundbreaking research capable of pushing the frontiers of science and technology for societal benefit.